Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2022

January 2022 | 70 pages | ID: T355F50F2A4AEN
DelveInsight

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight’s, “Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Type-2 fibroblast growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type-2 fibroblast growth factor receptor antagonists Understanding

Type-2 fibroblast growth factor receptor antagonists: Overview

Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm. FGF2 signals through four receptor tyrosine kinases (FGF receptor 1 through FGF receptor 4) and acts in a variety of developmental processes, including angiogenesis. FGF-2 exerts both proliferative and anti-apoptotic effects in osteoblasts.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Type-2 fibroblast growth factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Type-2 fibroblast growth factor receptor antagonists.

Type-2 fibroblast growth factor receptor antagonists Emerging Drugs Chapters

This segment of the Type-2 fibroblast growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type-2 fibroblast growth factor receptor antagonists Emerging Drugs

• Pemazyre (pemigatinib): Incyte Corporation

Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations. Pemazyre is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.

• Lenvatinib: Eisai

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFR?), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.

Further product details are provided in the report……..

Type-2 fibroblast growth factor receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Type-2 fibroblast growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Type-2 fibroblast growth factor receptor antagonists

There are approx. 15+ key companies which are developing the Type-2 fibroblast growth factor receptor antagonists. The companies which have their Type-2 fibroblast growth factor receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Incyte Corporation.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Type-2 fibroblast growth factor receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type-2 fibroblast growth factor receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type-2 fibroblast growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type-2 fibroblast growth factor receptor antagonists drugs.

Type-2 fibroblast growth factor receptor antagonists Report Insights

• Type-2 fibroblast growth factor receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Type-2 fibroblast growth factor receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Type-2 fibroblast growth factor receptor antagonists drugs?
• How many Type-2 fibroblast growth factor receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type-2 fibroblast growth factor receptor antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type-2 fibroblast growth factor receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type-2 fibroblast growth factor receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eisai
• Incyte Corporation
• AiViva BioPharma
• Boehringer Ingelheim
• Bayer Healthcare
• Advenchen Laboratories
• Abbisko Therapeutics
• Avalyn Pharmaceuticals
• Debiopharm
• Eli Lilly and Company
• Hutchison MediPharma
• Servier
• Astellas Pharma
• Taiho Oncology
• Russian Pharmaceutical Technologies
• Novartis

Key Products

• Lenvatinib
• Pemigatinib
• AIV 007
• Nintedanib
• Infigratinib
• Regorafenib
• RPT-835
• Lucitanib
• TAS 120
• ABSK 091
• AP02
• ASP 5878
• E 7090
• S 49076
• Zoligratinib
• LY 2874455
• HMPL 453

Contents

Introduction
Executive Summary
Type-2 fibroblast growth factor receptor antagonists: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Type-2 fibroblast growth factor receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
HMPL 453: Hutchison MediPharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
Lenvatinib - AiViva BioPharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
AP02: Avalyn Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Type-2 fibroblast growth factor receptor antagonists Key Companies
Type-2 fibroblast growth factor receptor antagonists Key Products
Type-2 fibroblast growth factor receptor antagonists- Unmet Needs
Type-2 fibroblast growth factor receptor antagonists- Market Drivers and Barriers
Type-2 fibroblast growth factor receptor antagonists- Future Perspectives and Conclusion
Type-2 fibroblast growth factor receptor antagonists Analyst Views
Type-2 fibroblast growth factor receptor antagonists Key Companies
Appendix